102 related articles for article (PubMed ID: 19863618)
1. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
Kowalska JD; Kirk O; Mocroft A; Høj L; Friis-Møller N; Reiss P; Weller I; Lundgren JD
HIV Med; 2010 Mar; 11(3):200-8. PubMed ID: 19863618
[TBL] [Abstract][Full Text] [Related]
2. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
[TBL] [Abstract][Full Text] [Related]
3. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
[TBL] [Abstract][Full Text] [Related]
4. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
[No Abstract] [Full Text] [Related]
5. Anti-HIV agents. Controversial findings on abacavir and heart attacks.
TreatmentUpdate; 2008 Mar; 20(2):1-5. PubMed ID: 18661643
[No Abstract] [Full Text] [Related]
6. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
[TBL] [Abstract][Full Text] [Related]
7. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.
Satchell CS; O'Halloran JA; Cotter AG; Peace AJ; O'Connor EF; Tedesco AF; Feeney ER; Lambert JS; Sheehan GJ; Kenny D; Mallon PW
J Infect Dis; 2011 Oct; 204(8):1202-10. PubMed ID: 21917893
[TBL] [Abstract][Full Text] [Related]
8. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
Law MG; Friis-Møller N; El-Sadr WM; Weber R; Reiss P; D'Arminio Monforte A; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Kirk O; Sabin CA; Phillips AN; Lundgren JD;
HIV Med; 2006 May; 7(4):218-30. PubMed ID: 16630034
[TBL] [Abstract][Full Text] [Related]
9. Heart attack risk with abacavir and didanosine.
AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
[No Abstract] [Full Text] [Related]
10. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
; Sabin CA; Worm SW; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; D'Arminio Monforte A; Friis-Møller N; Kirk O; Pradier C; Weller I; Phillips AN; Lundgren JD
Lancet; 2008 Apr; 371(9622):1417-26. PubMed ID: 18387667
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.
Hammond E; McKinnon E; Mallal S; Nolan D
AIDS; 2008 Nov; 22(18):2540-3. PubMed ID: 19005279
[No Abstract] [Full Text] [Related]
12. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J
J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804
[TBL] [Abstract][Full Text] [Related]
13. FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
AIDS Alert; 2008 May; 23(5):58-9. PubMed ID: 18642404
[No Abstract] [Full Text] [Related]
14. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
[TBL] [Abstract][Full Text] [Related]
15. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
Testa L; Van Gaal WJ; Biondi Zoccai GG; Agostoni P; Latini RA; Bedogni F; Porto I; Banning AP
QJM; 2009 Jun; 102(6):369-78. PubMed ID: 19286891
[TBL] [Abstract][Full Text] [Related]
16. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management.
Calza L; Manfredi R; Verucchi G
AIDS; 2010 Mar; 24(6):789-802. PubMed ID: 20224307
[No Abstract] [Full Text] [Related]
17. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
18. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
[TBL] [Abstract][Full Text] [Related]
20. Abacavir and cardiovascular risk.
Behrens GM; Reiss P
Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
